INOVIQ Croissance future

Future contrôle des critères 2/6

INOVIQ devrait augmenter ses bénéfices et ses revenus de 26% et de 70.9% par an respectivement, tandis que le BPA devrait croître de croître de 32.1% par an.

Informations clés

26.0%

Taux de croissance des bénéfices

32.1%

Taux de croissance du BPA

Healthcare croissance des bénéfices	24.7%
Taux de croissance des recettes	70.9%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	27 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

Apr 22

A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)

Mar 01

We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

Nov 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)

Mar 02

BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans

Dec 28

Prévisions de croissance des bénéfices et des revenus

ASX:IIQ - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2027	15	-2	-2	-1	1
6/30/2026	8	-6	-5	-5	1
6/30/2025	2	-9	-8	-8	1
6/30/2024	2	-7	-4	-4	N/A
3/31/2024	2	-7	-5	-5	N/A
12/31/2023	2	-7	-6	-5	N/A
9/30/2023	2	-8	-6	-6	N/A
6/30/2023	2	-9	-7	-7	N/A
3/31/2023	2	-15	-7	-6	N/A
12/31/2022	2	-21	-6	-6	N/A
9/30/2022	2	-20	-6	-6	N/A
6/30/2022	2	-18	-7	-6	N/A
3/31/2022	2	-14	-6	-6	N/A
12/31/2021	1	-11	-6	-5	N/A
9/30/2021	1	-11	-6	-5	N/A
6/30/2021	1	-11	-6	-5	N/A
3/31/2021	1	-8	-6	-5	N/A
12/31/2020	1	-5	-5	-5	N/A
9/30/2020	1	-4	-4	-4	N/A
6/30/2020	1	-3	-3	-3	N/A
3/31/2020	1	-3	-2	-2	N/A
12/31/2019	0	-2	-2	-2	N/A
9/30/2019	1	-2	-2	-2	N/A
6/30/2019	1	-2	-2	-2	N/A
3/31/2019	0	-2	-2	-2	N/A
12/31/2018	0	-2	-2	-2	N/A
9/30/2018	0	-2	-2	-2	N/A
6/30/2018	0	-2	-2	-2	N/A
3/31/2018	0	-2	N/A	-2	N/A
12/31/2017	0	-2	N/A	-2	N/A
9/30/2017	0	-2	N/A	-2	N/A
6/30/2017	0	-3	N/A	-2	N/A
6/30/2016	N/A	-6	N/A	0	N/A
12/31/2015	N/A	0	N/A	0	N/A
12/31/2014	N/A	0	N/A	0	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: IIQ devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: IIQ devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: IIQ devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de IIQ ( 70.9% par an) devrait croître plus rapidement que le marché Australian ( 5.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de IIQ ( 70.9% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de IIQ devrait être élevé dans 3 ans

INOVIQ Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 17%

Recent updates

INOVIQ Ltd, Annual General Meeting, Nov 28, 2024

Consensus EPS estimates fall by 17%

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

INOVIQ Ltd to Report Fiscal Year 2024 Results on Aug 21, 2024

INOVIQ Ltd has completed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Shareholder dilution

INOVIQ Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Share price stability

We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)

We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

INOVIQ Ltd, Annual General Meeting, Nov 28, 2023

Full year 2023 earnings released: AU$0.097 loss per share (vs AU$0.20 loss in FY 2022)

Insufficient new directors

Inoviq Limited Announces Clinical Validation Study for Subb2m/Ca15-3 Breast Cancer Test

New minor risk - Share price stability

Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

First half 2023 earnings released: AU$6.70 loss per share (vs AU$0.031 loss in 1H 2022)

Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

INOVIQ Limited Announces Positive Results for SubB2M Breast Cancer Test

INOVIQ Ltd Announces Resignation of Professor Allan Cripps AO as Director

INOVIQ Limited Announces Company Secretary Changes

INOVIQ Ltd, Annual General Meeting, Nov 28, 2022

INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans

Full year 2022 earnings released: AU$0.072 loss per share (vs AU$0.14 loss in FY 2021)

High number of new directors

INOVIQ Limited Announces Positive SubB2M IHC Results for Melanoma

We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely

High number of new and inexperienced directors

INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC

INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC

Inoviq Limited Announces Update on Legal Proceedings and Bard1 Autoantibody Program

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We're Keeping An Eye On INOVIQ's (ASX:IIQ) Cash Burn Rate

Full year 2021 earnings released: AU$0.14 loss per share (vs AU$0.072 loss in FY 2020)

Chief Scientific Officer Peter French has left the company

Chief Scientific Officer Peter French has left the company

BARD1 Life Sciences Limited Announces That Previously Reported Study Results for A Potential Bard1 Autoantibody Test for Early Detection of Ovarian Cancer in the International Peer-Reviewed Journal Genes

BARD1 Life Sciences Limited Announces SubB2M Breast Cancer Test Manuscript Submitted

Bard1 Life Sciences Limited Announces the Results of A Preliminary Study Which Demonstrates the Feasibility of Using Subb2m in an Ihc Application for Breast Cancer Tissue

BARD1 Life Sciences Limited Launches Its RUO EXO-NET Product

BARD1 Life Sciences Limited Presents BARD1 EXO-NET Exosome Data at ISEV2021 Conference

BARD1 Life Sciences Limited Announces Positive Results from the BARD1 autoantibody assay

BARD1 Life Sciences Limited Announces Positive Results Evaluation of EXO-NET in Pancreatic Cancer

BARD1 Life Sciences Limited Receives the Initial Purchase Order for AUD 80,000 from Mirax for hTERT

Bard1 Life Sciences Limited Gains Class II In-Vitro Diagnostic Medical Device Registration from South Korea's Ministry of Food and Drug Safety for the hTERT Test

Are Insiders Selling BARD1 Life Sciences Limited (ASX:BD1) Stock?

Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)

Insider recently sold AU$8.2m worth of stock

BARD1 Life Sciences Limited Releases SUBB2M BREAST CANCER TEST DATA

Bard1 Life Sciences Limited Announces Outstanding SubB2M Ovarian Cancer Test Data

New 90-day low: AU$0.57

Dr. Irmgard Irminger-Finger Steps Down from Board of BARD1 Life Sciences Limited

New 90-day low: AU$0.61

BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans

New 90-day low: AU$0.66

New 90-day low: AU$0.66

BARD1 Life Sciences Limited Announces Resignation of Helen Fisher as Non-executive Director

BARD1 Life Sciences Limited Gains New High-Volume Customer for Its hTERT test

BARD1 Life Sciences Limited Announces the Successful Evaluation of the BARD1 kit

BARD1 Life Sciences Limited Auditor Raises 'Going Concern' Doubt

Earnings released

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance